Fitusiran

PubChem compound: 119058042

Mechanism of action

Fitusiran is a double-stranded siRNA that causes degradation of AT messenger RNA (mRNA) through RNA interference, reducing plasma AT levels.

Pharmacodynamic properties

In clinical studies with fitusiran in hemophilia patients, the primary pharmacodynamic (PD) measure was plasma AT activity. Lower AT activity levels were associated with lower annualized bleeding rates (ABR); however, persistent AT activity <15% is a risk factor for thrombotic events.

In Study LTE15174, the mean (SD) AT activity on the AT-DR was 24% (4.64).

Simulations to estimate time for AT activity to reach steady state found that regardless of the dose regimen, more than 99% of participants reached steady state AT levels (defined as <10% variability among consecutive measures) within 23 weeks following initiation of fitusiran dosing or following dose escalation or de-escalation. The duration of persistent AT activity <60% (non-negligible impact of fitusiran on coagulation) following fitusiran treatment discontinuation was estimated to be approximately 6 months, after which standard doses of CFC/BPA may be administered. In patients with AT activity <15%, the time required prior to initiation of a lower dose was estimated to be 12 weeks to maximize the AT activity recovery to the target range of 15% to 35%. Extent of AT reduction with fitusiran did not differ between patients with hemophilia A or B, with or without inhibitors.

Pharmacokinetic properties

The pharmacokinetic (PK) properties of fitusiran were evaluated following administration of fitusiran in patients with hemophilia A or B, with or without inhibitors as summarized in the table below. Fitusiran PD is driven by liver PK rather than plasma PK. The fitusiran dosing strategy is based on maintaining plasma AT activity levels between 15–35% with 10, 20 or 50 mg dosing every month or every two months.

Pharmacokinetic Parameters of Fitusiran:

PK Parameters*Fitusiran 20 mgFitusiran 50 mg
General Information
Steady State Exposure:  
Cmax (ng/mL)34.4 (10.1) [29%]84.1 (58.7) [70%]
AUC (ng∙h/mL)491 (83.8) [17%]1290 (377) [29%]
Dose ProportionalityFitusiran exhibited a dose proportional increase in
plasma exposure after SC administration.
Accumulation†No accumulation of fitusiran was observed
following multiple once monthly dosing.
Absorption
tmax (h)2.88 (0.5 – 4.33)3.78 (0.42 – 11.9)
Distribution‡
Vss/F431 (135) [31%]570 (713) [125%]
Protein Binding§96.6% at clinically relevant exposure (0.5 microgram/ml)
Elimination
t1/2 (h)5.57 (2.36) [42%]7.98 (4.74) [59%]
CL/F41.9 (8.39) [20%]50.8 (71.1) [140%]
Metabolism
Primary PathwayFitusiran is metabolized by endo- and exo-
nucleases to oligonucleotides of varying lengths,
which are further metabolized to oligonucleotides
of even shorter lengths.
Fitusiran is not a substrate for CYP450 or
transporters.
Main MetaboliteAS(N-1)3'
Excretion
Primary PathwayNot evaluated14.6% (mean) of the
administered 50 mg
dose of fitusiran is
recovered unchanged in
0–24 hour urine

AUC = area under the plasma concentration-time curve extrapolated to infinity; CL/F = apparent clearance; Cmax = maximum plasma concentration; CV = coefficient of variation; PK = pharmacokinetic(s); SD = standard deviation; t1/2 = terminal elimination half-life; tmax = time to maximum concentration; Vss/F = apparent volume of distribution
* Unless otherwise indicated, the PK parameters in this table are from Study LTE15174. All PK parameters are estimated using non-compartmental analysis and are presented as Mean (SD) [CV%], except for tmax which is presented as median (range)
† Study TDR14767 (ALN-AT3SC-001)
‡ Fitusiran distributes primarily to the liver after subcutaneous injection.
§ In vitro data

Specific Populations

Fitusiran has only been studied in male patients. The pharmacokinetics of fitusiran is not influenced by race. fitusiran has not been studied in children <12 years old.

No clinical study to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of fitusiran was conducted. In the pivotal studies, 12 patients had mild renal impairment (eGFR ≥60 to <90 mL/min/1.73 m²) and 1 patient had moderate renal impairment (eGFR 30 mL/min/1.73 m² to <60 mL/min/1.73 m²). Population PK analysis indicated no impact of renal impairment on the exposure (Cmax and AUC) of fitusiran in patients with mild renal impairment.

Drug Interaction Studies

Clinical Studies

No clinical drug-drug interaction studies have been conducted to evaluate the potential of fitusiran to interact with other co-administered drugs which are either substrates, inhibitors or inducers of CYP isozymes, or are substrates or inhibitors of drug transporters.

In Vitro Studies

Results from in vitro studies evaluating the potential of co-administered drugs to increase the PK exposure of fitusiran, and the potential of fitusiran to increase the PK exposure of co-administered drugs, indicate that CYP- or transporter-mediated interactions between fitusiran and co-administered drugs are unlikely at clinically relevant concentrations.

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈